-
EP4355364
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4355364
| EP4355364 - ASSESSING AND TREATING PROSTATE CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.03.2024 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 23.12.2022 | Most recent event Tooltip | 22.03.2024 | Publication in section I.1 EP Bulletin | published on 24.04.2024 [2024/17] | 22.03.2024 | Request for examination filed | published on 24.04.2024 [2024/17] | Applicant(s) | For all designated states Mayo Foundation for Medical Education and Research 200 First Street S.W. Rochester, Minnesota 55905 / US | [2024/17] | Inventor(s) | 01 /
THALER, Roman Rochester, Minnesota 55902-2993 / US | 02 /
VAN WIJNEN, Andre J. Rochester, Minnesota 55902 / US | 03 /
LUCIEN-MATTEONI, Fabrice Rochester, Minnesota 55901-8497 / US | 04 /
DONG, Haidong Rochester, Minnesota 55902-2533 / US | 05 /
HUANG, Haojie Rochester, Minnesota 55906 / US | 06 /
PARK, Sean S. Rochester, Minnesota 55901 / US | 07 /
ORME, Jacob J. Rochester, Minnesota 55901-1783 / US | [2024/17] | Representative(s) | Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | [2024/17] | Application number, filing date | 22825885.1 | 17.06.2022 | [2024/17] | WO2022US33934 | Priority number, date | US202163211802P | 17.06.2021 Original published format: US 202163211802 P | [2024/17] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022266413 | Date: | 22.12.2022 | Language: | EN | [2022/51] | Type: | A1 Application with search report | No.: | EP4355364 | Date: | 24.04.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.12.2022 takes the place of the publication of the European patent application. | [2024/17] | Search report(s) | International search report - published on: | US | 22.12.2022 | Classification | IPC: | A61K41/00, G01N30/72 | [2024/17] | CPC: |
G01N30/88 (EP);
A61K31/167 (EP);
A61K31/277 (EP);
A61K31/4155 (EP);
A61K31/4166 (EP);
A61K31/4439 (EP);
A61K31/454 (EP);
A61K31/4709 (EP);
A61K31/496 (EP);
A61K31/502 (EP);
A61K31/5025 (EP);
A61K31/517 (EP);
A61K31/5377 (EP);
A61K31/55 (EP);
A61K31/58 (EP);
| C-Set: |
A61K31/167, A61K2300/00 (EP);
A61K31/277, A61K2300/00 (EP);
A61K31/4155, A61K2300/00 (EP);
A61K31/4166, A61K2300/00 (EP);
A61K31/4439, A61K2300/00 (EP);
A61K31/454, A61K2300/00 (EP);
A61K31/4709, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (EP);
A61K31/5025, A61K2300/00 (EP);
A61K31/502, A61K2300/00 (EP);
A61K31/517, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/17] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | BEURTEILUNG UND BEHANDLUNG VON PROSTATAKREBS | [2024/17] | English: | ASSESSING AND TREATING PROSTATE CANCER | [2024/17] | French: | ÉVALUATION ET TRAITEMENT DU CANCER DE LA PROSTATE | [2024/17] | Entry into regional phase | 17.01.2024 | National basic fee paid | 17.01.2024 | Search fee paid | 17.01.2024 | Designation fee(s) paid | 17.01.2024 | Examination fee paid | Examination procedure | 17.01.2024 | Amendment by applicant (claims and/or description) | 17.01.2024 | Examination requested [2024/17] | Fees paid | Renewal fee | 17.01.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2005036986 (THOMPSON TIMOTHY C [US]) [A] 1-3* entire document *; | [A]US2014363438 (JACKSON ERICA [US], et al) [A] 1-3 * entire document *; | [Y]WO2017223344 (UNIV COLUMBIA [US]) [Y] 1-3 * entire document *; | [A]US2021010084 (KONG GU [KR], et al) [A] 1-3 * entire document *; | [A]US10900086 (BOWDEN MICHAELA [US], et al) [A] 1-3 * entire document *; | [Y] - Zhang Zeda; Karthaus Wouter R.; Lee Young Sun; Gao Vianne R.; Wu Chao; Russo Joshua W.; Liu Menghan; Mota Jose Mauricio; Abida Wassim; Linton Eliot; Lee Eugine; Barnes Spencer D.; Chen Hsuan-An; Mao Ninghui; Wongvipat John; Choi Danielle; Chen Xiaoping; Zhao Huiyong; Manova-Todorova Katia; de Stanchina Elisa; Taplin Mary-Ellen; Balk Steven P.; Rathkopf Dana E.; Gopalan Anuradha; Carver Brett S.; Mu Ping; Jiang Xuejun; Watson Philip A.; Sawyers Charles L., "Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer", CANCER CELL, CELL PRESS, US, US , (20200716), vol. 38, no. 2, doi:10.1016/j.ccell.2020.06.005, ISSN 1535-6108, page 279, XP086244305 [Y] 1-3 * . entire document * DOI: http://dx.doi.org/10.1016/j.ccell.2020.06.005 |